狂野欧美激情性xxxx欧美I 成人性生交大片免费看中文网站I 日韩视频一区二区在线I 国产中的精品av小宝探花I 黄色国产在线I 久久精品视频在线观看I 在线天堂8√

熱門搜索:A549    293T 金黃色葡萄球菌 大腸桿菌 AKK菌
購物車 1 種商品 - 共0元
當前位置: 首頁 > ATCC代理 > 2B8
最近瀏覽歷史
聯系我們
  • 0574-87157013
  • mingzhoubio@163.com
  • 浙江省寧波市鎮海區莊市街道興莊路9號
  • 創e慧谷42號樓B幢401室
2B8
2B8
規格:
貨期:
編號:B200364
品牌:Mingzhoubio

標準菌株
定量菌液
DNA
RNA

規格:
凍干粉
斜面
甘油
平板


產品名稱 2B8
商品貨號 B200364
Organism Homo sapiens, human
Tissue ascites
Cell Type B lymphocyte; transfected with plasmid pSV2ne
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 Cells contain EBV particles

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease Burkitt's lymphoma
Age 7 years
Ethnicity Black, African
Applications
The 2B8 cell line (ATCC CRL-12569) is a HAT sensitive fusion cell line derived from the P3HR-1 Burkitt's lymphoma cell line (ATCC HTB-62).
Storage Conditions liquid nitrogen vapor temperature
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Images
Derivation
The 2B8 cell line (ATCC CRL-12569) is a HAT sensitive fusion cell line derived from the P3HR-1 Burkitt's lymphoma cell line (ATCC HTB-62). P3HR1 cells harbor non-immortalizing EBV. P3HR-1 cells were cloned; treated with methanesulfonic acid ethyl ester (MSE) and plated in medium containing 6-thioguanine (6TG). They were selected for deficiency in hypoxanthine-guanine phosphoribosyl transferase (HGPRT-, HPRT-). One of the clones was transfected with the neomycin resistance expression vector pSV2-neo to obtain the 2B8 cell line.
Clinical Data
Black, African
7 years
Comments
The 2B8 cell line (ATCC CRL-12569) is a HAT sensitive fusion cell line derived from the P3HR-1 Burkitt's lymphoma cell line (ATCC HTB-62). P3HR1 cells harbor non-immortalizing EBV. P3HR-1 cells were cloned; treated with methanesulfonic acid ethyl ester (MSE) and plated in medium containing 6-thioguanine (6TG). They were selected for deficiency in hypoxanthine-guanine phosphoribosyl transferase (HGPRT-, HPRT-). One of the clones was transfected with the neomycin resistance expression vector pSV2-neo to obtain the 2B8 cell line.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing
Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation and subsequent resuspension at 1 to 2 x 105 viable cells/mL. Maintain cell concentration between 1 x 105 and 1 x 106 cells/mL.
Medium Renewal: Every 2 to 3 days
Cryopreservation

Complete growth medium described above supplemented with 5% (v/v) DMSO.  Cell culture tested DMSO is available as ATCC Catalog No. 4-X.

Culture Conditions
Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5%
Name of Depositor Bayer Corporation
U.S. Patent Number
References

Cho MS. Human hybrid host cell for mammalian gene expression . US Patent 6,136,599 dated Oct 24 2000

Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC.

Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988.

Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC.

梅經理 17280875617 1438578920
胡經理 13345964880 2438244627
周經理 17757487661 1296385441
于經理 18067160830 2088210172
沈經理 19548299266 2662369050
李經理 13626845108 972239479
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |